logo image
search icon
Global Deep Vein Thrombosis Market

Deep Vein Thrombosis Market Size, Share & Trends Analysis Report By Treatment (Clot Busters, Blood Thinners, Inferior Vena Cava Filters, Compression Stockings, Others), By Distribution Channel, Region And Segment Forecasts, 2023-2031.

Report ID : 1070 | Published : 2023-07-26 | Pages: 180 | Format: PDF/EXCEL

The Deep Vein Thrombosis Market Size is valued at 958.11 Million in 2022 and is predicted to reach 1343.86 Million by the year 2031 at a 4.0 % CAGR during the forecast period for 2023-2031.

Deep Vein Thrombosis Market

Deep vein thrombosis (DVT) is a serious condition that occurs when clots forms in the deep veins of the body. The most dangerous complication of deep vein thrombosis is pulmonary embolism (PE), which can either be asymptomatic or symptomatic. Surgery and pregnancy are the major risk factors associated with deep vein thrombosis. Pregnancy increase hormone level and slower blood flow lead to expansion of uterus and restrict blood flowing back from lower extremities responsible for deep vein thrombosis. Diagnosis of deep vein thrombosis can be made with blood tests such as D-dimer test and imaging tests such as Doppler ultrasound (Duplex), contrast venogram, magnetic resonance imaging (MRI), and computer tomography (CT). There are four types of treatments for deep vein thrombosis include anticoagulant, thrombolytic therapy, IVC filters (Vein Filters), and Stents. Anticoagulant such as unfractionated heparin, low molecular weight heparin (enoxaparin/ Lovenox, dalteparin/Fragmin, or tinzaparin/Innohep, fondaparinux/Arixtra or desirudin/Iprivask), warfarin (Coumadin and Jantoven) are the primary treatment deep vein thrombosis. Thrombolytic therapy such as tissue plasminogen activator agents (tPA) can help to dissolve the blood clot. IVC filters (Vein Filters), also known as “Greenfield filters,” is an umbrella-shaped device that is placed into the large vein, which traps blood clots and prevents deep vein thrombosis and pulmonary embolism. Stents are metal meshwork tubes that are placed into a vein to keep them open.

Market Segmentation

Deep Vein Thrombosis market is segmented into Treatement, Distribution channel and Region. On the basis of Treatment, market is segmented into Clot Busters, Blood Thinners, Inferior Vena Cava Filters, Compression Stockings, Others, on the other side, By Distribution Channel, market is devided into Retail Pharmacy, Hospital Pharmacy, and E-commerce. Regionally, market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Almost one-half million patients are hospitalized for venous thromboembolism (consist of deep vein thrombosis and pulmonary embolism) each year in the United States. In Europe, there are 544,000 venous thromboembolism related death every year. Venous thromboembolism can cause a significant global economic burden. Various diagnostic tests and treatment, prolonged hospital stay, and follow-up care can be extremely costly; for instance estimated medical cost for venous thromboembolism in the U.S is $5-10 billion per year. In U.K venous thromboembolism related cost is 750 million per year. In Australia, venous thromboembolism related costs are estimated at 1.72 billion a year. In June 2017, U.S. FDA (Food and Drug Administration) approved betrixaban (Portola) for the adult with venous thromboembolism (VTE). Pentasaccharides such XARELTO are novel anticoagulants may be preferred over standard therapy due to few drug interactions and no need for frequent monitoring or re-dosing.

Competitive Landscape

Some of The Key Players in The Deep Vein Thrombosis Market:

  • Sandoz Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Sanofi-Aventis U.S. LLC,
  • Baxter International Inc.,
  • West-Ward Pharmaceuticals,
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Abbott Laboratories,
  • Bristol-Myers Squibb Company,
  • Pfizer,
  • Daiichi Sankyo Co. Ltd.,
  • Medtronic plc,
  • Johnson & Johnson,

The Deep Vein Thrombosis Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD 958.11 Million

Revenue Forecast In 2031

USD 1343.86 Million

Growth Rate CAGR

CAGR of 4.0 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Treatment, By Distribution Channel

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Sandoz Inc. Teva Pharmaceuticals USA, Inc. Sanofi-Aventis U.S. LLC, Baxter International Inc., West-Ward Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc. Abbott Laboratories, Bristol-Myers Squibb Company, Pfizer, Daiichi Sankyo Co. Ltd., Medtronic plc, Johnson & Johnson, and others.

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

 

 

 

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Deep Vein Thrombosis Market Snapshot

Chapter 4. Global Deep Vein Thrombosis Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

4.9. Clinical Trial/Pipeline Analysis

Chapter 5. Market Segmentation 1: By Treatment Estimates & Trend Analysis

5.1. By Treatment & Market Share, 2019 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Treatment:

5.2.1. Clot Busters

5.2.2. Blood Thinners

5.2.3. Inferior Vena Cava Filters

5.2.4. Compression Stockings

5.2.5. Others

Chapter 6. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis

6.1. By Distribution Channel & Market Share, 2019 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Distribution Channel:

6.2.1. Hospital Pharmacy

6.2.2. Retail Pharmacy

6.2.3. Online Pharmacy

Chapter 7. Deep Vein Thrombosis Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Treatment, 2023 - 2031

7.1.2. North America Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031

7.1.3. North America Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts by country, 2023 - 2031

7.2. Europe

7.2.1. Europe Deep Vein Thrombosis Market revenue (US$ Million) By Treatment, 2023 - 2031

7.2.2. Europe Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031

7.2.3. Europe Deep Vein Thrombosis Market revenue (US$ Million) by country, 2023 - 2031

7.3. Asia Pacific

7.3.1. Asia Pacific Deep Vein Thrombosis Market revenue (US$ Million) By Treatment, 2023 - 2031

7.3.2. Asia Pacific Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031

7.3.3. Asia Pacific Deep Vein Thrombosis Market revenue (US$ Million) by country, 2023 - 2031

7.4. Latin America

7.4.1. Latin America Deep Vein Thrombosis Market revenue (US$ Million) By Treatment, (US$ Million)

7.4.2. Latin America Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031

7.4.3. Latin America Deep Vein Thrombosis Market revenue (US$ Million) by country, (US$ Million) 2023 - 2031

7.5. Middle East & Africa

7.5.1. Middle East & Africa Deep Vein Thrombosis Market revenue (US$ Million) By Treatment, (US$ Million)

7.5.2. Middle East & Africa Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031

7.5.3. Middle East & Africa Deep Vein Thrombosis Market revenue (US$ Million) by country, (US$ Million) 2023 - 2031

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Sandoz Inc.

8.2.2. Teva Pharmaceuticals USA, Inc.

8.2.3. Sanofi-Aventis U.S. LLC,

8.2.4. Baxter International Inc.,

8.2.5. West-Ward Pharmaceuticals,

8.2.6. Boehringer Ingelheim Pharmaceuticals, Inc.

8.2.7. Abbott Laboratories,

8.2.8. Bristol-Myers Squibb Company,

8.2.9. Pfizer,

8.2.10. Daiichi Sankyo Co. Ltd.,

8.2.11. Medtronic plc,

8.2.12. Johnson & Johnson,

8.2.13. others

 

Segmentation of Deep Vein Thrombosis Market

Global Deep Vein Thrombosis Market Outlook By Treatment

  • Clot Busters
  • Blood Thinners
  • Inferior Vena Cava Filters
  • Compression Stockings
  • Others

Deep Vein Thrombosis Market

Global Deep Vein Thrombosis Market Outlook By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • E-commerce

Global Deep Vein Thrombosis Market Outlook By Region

  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia & New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Deep Vein Thrombosis Market Size?

The Deep Vein Thrombosis Market Size is valued at 958.11 Million in 2022 and is predicted to reach 1343.86 Million by the year 2031 at a 4.0 % CAGR du

Sandoz Inc. Teva Pharmaceuticals USA, Inc. Sanofi-Aventis U.S. LLC, Baxter International Inc., West-Ward Pharmaceuticals, Boehringer Ingelheim Pharmac

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$3786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach